Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pardaxin** is a membrane-lysing antimicrobial peptide originally isolated from marine fish species including *Pardachirus marmoratus* and *Pardachirus pavovinus*. It consists of 33 amino acids and is recognized for its cytolytic and cytotoxic activity, including permeabilization of cell membranes by forming stable or transient pores[2][3][4]. It exhibits potent antimicrobial effects and has demonstrated antitumor properties in preclinical models by inhibiting cell proliferation, inducing apoptosis through both mitochondrial and death receptor/NF-κB pathways, and promoting differentiation and maturation of leukemic cells[3][5]. Additionally, pardaxin induces dopamine release from pheochromocytoma cells by activating arachidonic acid cascades and influencing phospholipase A2 and lipoxygenase pathways, independent of extracellular calcium[1]. Its mechanisms are multifactorial and include modulation of caspases, suppression of tumor cell growth, and membrane disruption[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pardaxin.